Alaunos Therapeutics Inc
$ 3.19
1.59%
27 Feb - close price
- Market Cap 7,119,500 USD
- Current Price $ 3.19
- High / Low $ 3.34 / 3.06
- Stock P/E N/A
- Book Value 1.27
- EPS -2.30
- Next Earning Report 2026-03-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.70 %
- ROE -1.46 %
- 52 Week High 5.48
- 52 Week Low 1.31
About
Alaunos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on discovering, acquiring, developing and commercializing a portfolio of immuno-oncology therapies to treat cancer patients. The company is headquartered in Houston, Texas.
Analyst Target Price
$1.75
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-14 | 2025-08-14 | 2025-05-13 | 2025-03-31 | 2024-11-12 | 2024-08-14 | 2024-04-01 | 2024-03-05 | 2023-11-14 | 2023-08-14 | 2023-05-10 | 2023-03-07 |
| Reported EPS | -0.55 | -0.63 | -0.6701 | -0.4634 | -0.7038 | -0.7051 | -0.49 | -0.49 | -0.04 | -0.04 | -0.04 | -0.04 |
| Estimated EPS | 0 | None | None | None | None | None | -0.45 | -0.45 | -0.04 | -0.04 | -0.04 | -0.07 |
| Surprise | -0.55 | 0 | 0 | 0 | 0 | 0 | -0.04 | -0.04 | 0 | 0 | 0 | 0.03 |
| Surprise Percentage | None% | None% | None% | None% | None% | None% | -8.8889% | -8.8889% | 0% | 0% | 0% | 42.8571% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-30 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TCRT
2025-12-24 16:09:54
Alaunos Therapeutics (NASDAQ:TCRT) has reached a settlement with The University of Texas M.D. Anderson Cancer Center to resolve disputes over unpaid invoices from a 2019 Research and Development Agreement. The biotechnology company will pay MD Anderson a total of $285,055 in installments through May 2026. The agreement includes mutual general releases of claims, with exceptions for breaches of the settlement and ongoing matters.
2025-12-24 00:09:03
Alaunos Therapeutics (NASDAQ:TCRT) has reached a settlement with The University of Texas M.D. Anderson Cancer Center to resolve disputes over unpaid invoices from a 2019 Research and Development Agreement. The company will pay MD Anderson a total of $285,055 in installments through May 2026. This agreement includes mutual releases of claims, with exceptions for breaches of the settlement and ongoing matters.
2025-10-22 11:31:49
PMGC Capital LLC, a subsidiary of PMGC Holdings Inc. (ELAB), announced its intention to file a Schedule 13D, disclosing a 5.09% beneficial ownership stake in Alaunos Therapeutics, Inc. (TCRT). PMGC Capital acquired 83,500 shares of Alaunos Therapeutics, driven by a belief that the company is undervalued and holds significant potential for shareholder value creation. PMGC Capital plans to engage with Alaunos' management and board to explore strategic opportunities, including potential mergers, acquisitions, or partnerships, particularly in financial technology and cryptocurrency sectors.
2025-10-22 11:31:49
Alaunos Therapeutics Inc. (TCRT) has shifted its strategic focus to an internally developed small molecule oral obesity program, ceasing development of its TCR-T clinical programs due to high costs. The company reported a net loss of $4.6 million for the year ended December 31, 2024, and faces substantial doubt about its ability to continue as a going concern without additional financing. Alaunos is exploring strategic alternatives while its stock remains listed on Nasdaq.
2025-10-15 06:51:47
Alaunos Therapeutics (NASDAQ:TCRT) has received a "Sell (D-)" rating from Weiss Ratings. The clinical-stage oncology company specializes in developing adoptive T-cell receptor engineered T-cell therapies (TCR-T) to treat various solid tumor types. The report comes as shares of Alaunos Therapeutics have recently increased by 5.5%.
2025-10-09 12:28:11
Alaunos Therapeutics Inc. (TCRT) stock has experienced an 18.11% surge despite a recent net loss of $1M and revenues of only $10,000, driven by investor optimism about potential strategic initiatives and R&D in cancer therapy. The company maintains a strong financial backbone with no long-term debt and a current ratio of 3.5, but its operational woes are highlighted by a negative profit margin. The article concludes that TCRT's future movements will likely be influenced by news developments and strategic maneuvers in its R&D labs, creating a volatile yet promising outlook for traders.
